Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThor Energy Regulatory News (THR)

Share Price Information for Thor Energy (THR)

Share Price is delayed by 15 minutes
Get Live Data
0.60    0.05 (9.09%)
Bid:
0.55
Ask:
0.65
Spread: 0.10 (18.182%)
Market Cap: £6.18m
THR Live PriceLast checked at - London Stock Exchange

Intraday Thor Energy Share Chart

Appendix 3B

6 Dec 2017 09:30

RNS Number : 5478Y
Thor Mining PLC
06 December 2017
Β 

Wednesday, 6 December 2017

Β 

THOR MINING PLC

Β ("Thor" or the "Company")

Β 

Appendix 3B

Β 

The Directors of Thor Mining PLC (AIM, ASX: THR) today released the following announcement on the Australian Securities Exchange ("ASX"), as required under the listing rules of the ASX.

Β 

Β 

Enquiries:

Mick Billing

+61 (8) 7324 1935

Thor Mining PLC

ExecutiveΒ Chairman

Ray Ridge

+61 (8) 7324 1935

Β 

Thor Mining PLC

CFO/Company

Secretary

Colin Aaronson/

Daniel Bush/

Richard Tonthat

+44 (0) 207 383 5100

Β 

Grant Thornton UK LLP

Β 

Nominated Adviser

Elliot Hance

Β +44 (0) 207382 8300

Beaufort Securities Limited

Joint Broker

Nick Emerson

+44 (0) 1483 413 500

SI Capital Ltd

Joint Broker

Tim Blythe/ Camilla Horsfall

+44 (0) 207 138 3222

Blytheweigh

Financial PR

Β 

Β 

Updates on the Company's activities are regularly posted on Thor's websiteΒ www.thormining.com, which includes a facility to register to receive these updates by email, and on the Company's twitter page @ThorMining.

Β 

Β 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

Β 

New issue announcement,

application for quotation of additional securities

and agreement

Β 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Β 

Β 

Name of entity

Thor Mining PLC

Β 

ABN

121 117 673

Β 

We (the entity) give ASX the following information.

Β 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

Β 

1

+Class of +securities issued or to be issued

Β 

(a) Ordinary shares / CDIs

(b) Ordinary shares

Β 

Β 

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

Β 

(a) Transfers of 846,482 to AIM listed shares on the AIM Market of the London Stock Exchange, from ASX listed CDI's, during the period 30 November 2017 to 5 December 2017.

(b) Issue of 8,472,381 Ordinary Shares as a result of options (termed warrants in the UK) being exercised.

Β 

The total number of securities, listed on both AIM and ASX, is now 583,588,251 as at 6 December 2017.

Β 

Β 

3

Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

This represents:

(a) Transfers between AIM listed shares on the AIM Market of the London Stock Exchange, and ASX listed CDI's.

(b) Issue of 8,472,381 Ordinary Shares as a result of the exercise of options.

Β 

4

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

Β 

If the additional securities do not rank equally, please state:

Β· the date from which they do

Β· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

(a) Yes.

(b) Yes.

Β 

5

Issue price or consideration

Β 

(a) N/A

(b) 7,520,000 at an exercise price of Β£0.0125 per share and 952,381 at an exercise price of Β£0.009.

Β 

Β 

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

Β 

Β 

Β 

Β 

Β 

Β 

(a) N/A

(b) Issue of Shares as a result of options being exercised. Cash consideration received per above.

Β 

Β 

Β 

Β 

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

Β 

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

Yes

Β 

Β 

Β 

Β 

6b

The date the security holder resolution under rule 7.1A was passed

29 November 2017

Β 

Β 

Β 

Β 

6c

Number of +securities issued without security holder approval under rule 7.1

N/A

Β 

Β 

Β 

Β 

6d

Number of +securities issued with security holder approval under rule 7.1A

N/A

Β 

Β 

Β 

Β 

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

Β 

N/A

Β 

Β 

Β 

Β 

6f

Number of securities issued under an exception in rule 7.2

(a) N/A

(b) 8,472,381 Ordinary Shares as a result of the exercise of options.

Β 

Β 

Β 

Β 

6g

If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

N/A

Β 

Β 

Β 

Β 

6h

If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements.

N/A

Β 

Β 

Β 

Β 

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

Refer attached Annexure 1

Β 

Β 

Β 

7

Dates of entering +securities into uncertificated holdings or despatch of certificates

(a) Transfers 30 November 2017 to 5 December 2017

(b) 6 December 2017

Β 

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the securities in section 2 if applicable)

Β 130,246,971

Β 

Ordinary Shares quoted by

ASX ("THR" as CDIs) as at 6 December 2017.

9

Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)

Β 

Β 

Β 

453,341,280

Β 

Β 

Β 

Β 

Β 

11,272,903

Β 

11,613,549

Β 

44,682,564

Β 

19,680,000

Β 

32,513,434

Β 

13,840,000

Β 

2,000,000

Β 

20,000,000

Β 

51,111,111

Β 

15,000,000

Β 

1,500,000

Β 

Ordinary Shares admitted to the AIM Market of the London Stock Exchange, as at 6 December 2017.

Β 

Unlisted Options:

0.9 pence unlisted warrants

Β expiring 27 July 2018.

1.2 pence unlisted warrants expiring 2 November 2018

1.2 pence unlisted warrants expiring 29 November 2018

1.25 pence unlisted warrants expiring 1 December 2018.

1.25 pence unlisted warrants expiring 7 April 2019.

1.25 pence unlisted warrants expiring 11 April 2019.

1.8 pence unlisted warrants

Β expiring 27 June 2019.

1.25 pence unlisted warrants expiring 26 July 2019.

1.8 pence unlisted warrants

Β expiring 28 July 2019.

1.8 pence unlisted warrants

Β expiring 31 March 2020.

1.8 pence unlisted warrants

Β expiring 27 June 2020.

Β 

Β 

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No Policy

Β 

Β 

Part 2 ‑ Bonus issue or pro rata issue - Not Applicable

Β 

Β 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

Β 

34

Type of securities

(tick one)

Β 

(a)

ΓΌ

Securities described in Part 1

Β 

(b)

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Β 

Entities that have ticked box 34(a)

Β Additional securities forming a new class of securities

Β 

Β 

Tick to indicate you are providing the information or documents

Β 

35

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

Β 

Β 

36

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

Β 

Β 

37

A copy of any trust deed for the additional +securities

Β 

Β 

Entities that have ticked box 34(b)

Β 

38

Number of securities for which +quotation is sought

Β 

Β 

Β 

39

Class of +securities for which quotation is sought

Β 

Β 

Β 

40

Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

Β 

If the additional securities do not rank equally, please state:

Β· the date from which they do

Β· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

Β· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Β 

Β 

Β 

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

Β 

(if issued upon conversion of another security, clearly identify that other security)

Β 

Β 

Β 

Β 

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the securities in clause 38)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Quotation agreement

Β 

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

Β 

2 We warrant the following to ASX.

Β 

Β· The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

Β 

Β· There is no reason why those +securities should not be granted +quotation.

Β 

Β· An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

Β 

Β· Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

Β 

Β· If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

Β 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

Β 

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Β 

Β 

Β 

Β 

Β 

Sign here: .............................. Date: 6 December 2017

(Company Secretary)

Β 

Print name: Ray Ridge

Β 

== == == == ==

Β 

Appendix 3B - Annexure 1

Β 

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Β 

Rule 7.1 - Issues exceeding 15% of capital

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue

as at 5 December 2016 317,158,340

Β 

Add the following:

β€’ Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2

β€’ Number of fully paid ordinary securities issued in that 12 month period with shareholder approval

β€’ Number of partly paid ordinary securities that became fully paid in that 12 month period

Note:

β€’ Include only ordinary securities here - other classes of equity securities cannot be added

β€’ Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

β€’ It may be useful to set out issues of securities on different dates as separate line items

Β 

Placement (27/1/17) 50,000,000

(approved 27 July 2017)

Β 

Issue - options exercised 1,780,026

(Issued 17/3/17)

Β 

Issue - options exercised 3,312,477

(Issued 20/3/17)

Β 

Issue - options exercised 762,365

(Issued 10/4/17)

Β 

Placement (28/7/17) 51,111,111

(approved 27 July 2017)

Β 

Placement (03/11/17) 29,473,686

(approved 29 November 2017)

Β 

Issue - options exercised 10,000,000

(Issued 10/11/17)

Β 

Issue - options exercised 20,730,855

(Issued 13/11/17)

Β 

Issue - options exercised 10,773,161

(Issued 15/11/17)

Β 

Issue - options exercised 20,749,484

(Issued 21/11/17)

Β 

Issue - options exercised 18,113,051

(Issued 29/11/17)

Β 

Placement (30/11/17) 41,151,314

(approved 29 November 2017)

Β 

Issue - options exercised 8,472,381

(Issued 6/12/17)

Subtract the number of fully paid ordinary securities cancelled during that 12 month period

0

Β 

"A"

583,588,251

Β 

Step 2: Calculate 15% of "A"

"B"

0.15

[Note: this value cannot be changed]

Multiply "A" by 0.15

87,538,237

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:

β€’ Under an exception in rule 7.2

β€’ Under rule 7.1A

β€’ With security holder approval under rule 7.1 or rule 7.4

Note:

β€’ This applies to equity securities, unless specifically excluded - not just ordinary securities

β€’ Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed

β€’ It may be useful to set out issues of securities on different dates as separate line items

Β 

Β 

Β 

Β 

Β 

Β 

"C"

0

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15

Note: number must be same as shown in Step 2

Β 

87,538,237

Subtract "C"

Note: number must be same as shown in Step 3

Β 

0

Total ["A" x 0.15] - "C"

87,538,237

Β [Note: this is the remaining placement capacity under rule 7.1]

Part 2

Β 

Rule 7.1A - Additional placement capacity for eligible entities

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"A"

Note: number must be same as shown in Step 1 of Part 1

Β 

583,588,251

Step 2: Calculate 10% of "A"

"D"

0.10

Note: this value cannot be changed

Multiply "A" by 0.10

58,358,825

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

β€’ This applies to equity securities - not just ordinary securities

β€’ Include here - if applicable - the securities the subject of the Appendix 3B to which this form is annexed

β€’ Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

β€’ It may be useful to set out issues of securities on different dates as separate line items

"E"

0

Β 

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10

Note: number must be same as shown in Step 2

Β 

58,358,825

Subtract "E"

Note: number must be same as shown in Step 3

Β 

0

Total ["A" x 0.10] - "E"

58,358,825

Note: this is the remaining placement capacity under rule 7.1A

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCGCBDDCDGBGRL
Date   Source Headline
28th Feb 201912:31 pmRNSHalf-year Report
4th Feb 20197:00 amRNSBonya Rock Chip Assays
1st Feb 201912:04 pmRNSAppointment of Joint Broker
31st Jan 20197:00 amRNSAPPENDIX 5B OCTOBER TO DECEMBER 2018
30th Jan 201911:10 amRNSQUARTERLY REPORT OCTOBER TO DECEMBER 2018
8th Jan 20198:20 amRNSInvestor Presentation
18th Dec 20187:00 amRNSKapunda Copper Project Proof of Concept
13th Dec 20188:20 amRNSPilot Mountain Increased Mineral Resource Estimate
10th Dec 20189:47 amRNSAppendix 3B
5th Dec 20187:05 amRNSExercise of Warrants
5th Dec 20187:00 amRNSAppendix 3B
30th Nov 20187:00 amRNSAnnual General Meeting Presentation
30th Nov 20187:00 amRNSHolding(s) in Company
28th Nov 20183:30 pmRNSExercise of Warrants
28th Nov 201810:17 amRNSResult of AGM
26th Nov 20184:40 pmRNSSecond Price Monitoring Extn
26th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20182:05 pmRNSSecond Price Monitoring Extn
26th Nov 20182:00 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSBonya Copper Maiden Resource Estimate
23rd Nov 20189:35 amRNSAppendix 3B
21st Nov 20189:59 amRNSIssue of Equity
20th Nov 20187:00 amRNSAppointment of Corporate Advisor - Molyhil
9th Nov 20187:00 amRNSAppendix 3B
5th Nov 20189:09 amRNSExercise of Warrants
2nd Nov 20187:00 amRNSAppendix 3B
31st Oct 20187:00 amRNSQUARTERLY REPORT JULY TO SEPTEMBER 2018
31st Oct 20187:00 amRNSAPPENDIX 5B JULY TO SEPTEMBER 2018
30th Oct 20187:00 amRNSWarrant Exercise - Director Dealing
29th Oct 20187:40 amRNSResearch Report
5th Oct 20189:43 amRNSAppendix 3B
4th Oct 201810:14 amRNSIssue of Shares for Bonya Acquisition
24th Sep 201811:02 amRNSBonya Licence Transfer Approved
21st Sep 201812:00 pmRNSFinal Results
11th Sep 20188:39 amRNSUS Lithium - Update on Sale Process
7th Sep 20188:48 amRNSPilot Mountain Scoping Study
28th Aug 20187:01 amRNSKapunda Project Laboratory Copper Extraction
23rd Aug 20187:15 amRNSUpgraded Definitive Feasibility Study - Molyhil
21st Aug 201811:05 amRNSSecond Price Monitoring Extn
21st Aug 201811:00 amRNSPrice Monitoring Extension
21st Aug 20187:00 amRNSTrading Halt on the ASX
6th Aug 20183:15 pmRNSUS Lithium Investment Update
6th Aug 201812:17 pmRNSAppendix 3B
6th Aug 20187:00 amRNSAppointment of Joint Broker
1st Aug 20189:40 amRNSAPPENDIX 5B TO QUARTERLY REPORT APRIL TO JUNE 2018
1st Aug 20189:19 amRNSQUARTERLY REPORT APRIL TO JUNE 2018
31st Jul 20187:00 amRNSExercise of warrants
30th Jul 20187:00 amRNSAppendix 3B
30th Jul 20187:00 amRNSKapunda Research Grant
23rd Jul 20183:22 pmRNSExercise of warrants

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.